# EDGAR Filing Document

**Accession Number:** 0001485894
**File Stem:** 0001193125-26-220726
**Filing Date:** 2026-5
**Character Count:** 6051
**Document Hash:** a1993b2a4f920e469823103c98c65656
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-220726.hdr.sgml**: 20260513

**ACCESSION NUMBER**: 0001193125-26-220726

**CONFORMED SUBMISSION TYPE**: 497K

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260513

**DATE AS OF CHANGE**: 20260513

**EFFECTIVENESS DATE**: 20260513

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** J.P. Morgan Exchange-Traded Fund Trust
- **CENTRAL INDEX KEY:** 0001485894

**ORGANIZATION NAME:**
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE

**FILING VALUES:**
- **FORM TYPE:** 497K
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-191837
- **FILM NUMBER:** 26971153

**BUSINESS ADDRESS:**
- **STREET 1:** 390 MADISON AVENUE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017
- **BUSINESS PHONE:** (800) 480-4111

**MAIL ADDRESS:**
- **STREET 1:** 390 MADISON AVENUE
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10017

## Series and Classes Contracts Data

### JPMorgan U.S. Research Enhanced Large Cap ETF (Series ID: S000090403)

| Class ID   | Class Name                                    | Ticker Symbol   |
|:---|:---|:---|
| C000257449 | JPMorgan U.S. Research Enhanced Large Cap ETF | JUSA            |

**J.P. MORGAN EXCHANGE-TRADED FUNDS** 

**JPMorgan U.S. Research Enhanced Large Cap ETF** 

*(the "Fund")* 

*(a series of J.P. Morgan Exchange-Traded Fund Trust)* 

**Supplement dated May 13, 2026** 

**to the current Summary Prospectus and Prospectus, as supplemented** 

Effective immediately, the management fee for the Fund is reduced from an annual rate of 0.20% of the Fund's average daily net assets to 0.18%. In addition, an expense limitation arrangement will be added for Shares of the Fund to further limit the Fund's net expense ratio. In connection with these changes, the "Annual Fund Operating Expenses" and "Example" tables for the Fund are hereby replaced with the corresponding tables below.

---

| | |
|:---|:---|
| &nbsp;&nbsp; **ANNUAL FUND OPERATING EXPENSES<sup>1</sup>**<br> **(Expenses that you pay each year as a percentage of the value of your investment)** | &nbsp;&nbsp; **ANNUAL FUND OPERATING EXPENSES<sup>1</sup>**<br> **(Expenses that you pay each year as a percentage of the value of your investment)** |
| &nbsp;&nbsp;&nbsp;**Management Fees<sup>2</sup>** | 0.18% |
| &nbsp;&nbsp;&nbsp;**Total Annual Fund Operating Expenses** | 0.18 |
| &nbsp;&nbsp;&nbsp;**Fee Waivers and or/ Expense Reimbursements<sup>3</sup>** | (0.06) |
| &nbsp;&nbsp;&nbsp;**Total Annual Fund Operating Expenses after Fee Waivers and/or Expense Reimbursements<sup>3</sup>** | 0.12 |

---

---

| | |
|:---|:---|
| 1 | The Fund's management agreement provides that the adviser will pay substantially all expenses of the Fund (including expenses of the Trust relating to the Fund), except for the management fees, payments under the Fund's 12b-1 plan (if any), interest expenses, dividend and interest expenses related to short sales, taxes, acquired fund fees and expenses (other than fees for funds advised by the adviser and/or its affiliates), costs of holding shareholder meetings, and litigation and potential litigation and other extraordinary expenses not incurred in the ordinary course of the Fund's business. Additionally, the Fund shall be responsible for its non-operating expenses, including brokerage commissions and fees and expenses associated with the Fund's securities lending program, if applicable.  |

---

---

| | |
|:---|:---|
| 2 | The management fee has been restated to reflect the reduction of the fee to 0.18% of the Fund's average daily net assets effective May 13, 2026.  |

---

---

| | |
|:---|:---|
| 3 | The Fund's adviser has contractually agreed to waive fees and/or reimburse expenses to the extent Total Annual Fund Operating Expenses (excluding acquired fund fees and expenses other than certain money market fund fees as described below, dividend and interest expenses related to short sales, interest, taxes, expenses related to litigation and potential litigation, costs of shareholder meetings, and extraordinary expenses) exceed 0.12% of the average daily net assets of the Fund. The Fund may invest in one or more money market funds advised by the adviser or its affiliates (affiliated money market funds). The Fund's adviser has contractually agreed to waive fees and/or reimburse expenses in an amount sufficient to offset the fees and expenses of the affiliated money market funds incurred by the Fund because of the Fund's investment in such money market funds. These contractual waivers are in effect through 10/31/2027, at which time the adviser expects to charge the full Management Fee of 0.18% of average daily net assets. To the extent that the Fund engages in securities lending, affiliated money market fund fees and expenses resulting from the Fund's investment of cash received from securities lending borrowers are not included in Total Annual Fund Operating Expenses and therefore, the above contractual waivers do not apply to such investments.  |

---

**Example** 

This Example is intended to help you compare the cost of investing in the Fund with the cost of investing in other funds. The Example does not take into account brokerage commissions that you pay when purchasing or selling Shares of the Fund. The Example assumes that you invest $10,000 in the Fund for the time periods indicated. The Example also assumes that your investment has a 5% return each year and that the Fund's operating expenses are equal to the total annual fund operating expenses after fee waivers and expense reimbursements shown in the fee table through 10/31/27 and total annual fund operating expenses thereafter. Your actual costs may be higher or lower.

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;**WHETHER OR NOT YOU SELL YOUR SHARES, YOUR COST WOULD BE:** | | |
|  |<br>**1 Year** |<br>**3 Years** |
| &nbsp;&nbsp;&nbsp;**SHARES ($)** | 12 | 49 |

---

**INVESTORS SHOULD RETAIN THIS SUPPLEMENT WITH THE** 

**SUMMARY PROSPECTUS AND PROSPECTUS FOR FUTURE REFERENCE** 

**SUP-USRELCETF-526**